In a recent development within the pharmaceutical industry, GlaxoSmithKline PLC and Pfizer Inc. have agreed to a resolution in their ongoing patent dispute. The legal contention centered around Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo. GSK alleged that Pfizer’s vaccine infringed on their patents, a claim Pfizer contested by arguing the patents in question were either invalid or unenforceable.
This agreement concludes a significant legal battle between the two industry giants, originating from GSK’s assertion of its intellectual property rights over innovations related to the RSV vaccine. The resolution terms remain undisclosed at this time, however, the settlement allows both companies to focus on the further development and distribution of their own RSV vaccines without the looming threat of litigation. For a more detailed account, visit the full article on Law360.